Onco Actu du 3 décembre 2015

	2. Etiologie
The Bigger Picture - What’s luck got to do with it? [The Institute of Cancer Research] But for all this complexity, there is a clear clue to the right answer from the documented variation in incidence rates. This suggests to me that up to some 90% of common cancers could, given sufficient knowledge and applied effort, be prevented or avoided. Now I’m dreaming. But I’m probably not alone.
	2.6 Etiologie - Environnement
Arsenic & bladder cancer [Cancer Prevention Research & Policy Blog] Interventions should not just stop at changing the concentration of arsenic in drinking water, but should ensure that people who have been exposed to high levels of arsenic are targeted for screening programmes and other cancer prevention initiatives for many decades after arsenic exposure has decreased.
	3.3 Prévention - Vaccins
Grand Challenge one: can we develop a jab to prevent cancer? [Cancer Research UK] Helping the immune system destroy these abnormal cells before they develop into cancer could not only save lives, but spare thousands from even becoming a cancer patient in the first place. It sounds incredible – so how might this work in practice?
	4.9 Dép., diag. & prono. - Sein
Screen-Film Mammography Will Soon be ‘Virtually Obsolete,’ FDA Says [RAPS] The prediction comes as FDA on Tuesday officially announced that a North Carolina-based physician practice would no longer use screen-film mammograms after deficiencies were noted in the clinical image quality of images reviewed.
False-positive Mammograms May Indicate Increased Risk of Breast Cancer Later [AACR] “We don’t want women to read this and feel worried,” she said. “We intend for our findings to be a useful tool in the context of other risk factors and assessing overall breast cancer risk.
False positive mammograms linked to slight cancer risk increase [Reuters] “The higher risk of developing cancer among those with a false positive result with biopsy may be due to the fact that the radiologist sees an abnormal pattern that is not cancerous but is a radiographic marker associated with subsequent cancer.”
Study Suggests Breast Density Alone Not a Risk Factor for Cancer [RNSA] Researchers looked at data from 52,962 mammography exams performed in women ages 50 to 69 over five years.
	5. Traitements
Why Blocking microRNAs in Triple Negative Breast Cancer is so Difficult [GEN] "Rather than blocking miR-17, we were inadvertently boosting its levels, and, therefore, boosting the cell's cancerous potential."
	5.2.1 Pharma - Partenariats
Boehringer joins MD Anderson's cadre of cancer collaborators with pancreatic partnership [FierceBiotech] For Boehringer, the agreement fits in with the German drugmaker's vision for future R&D, relying more external partners than internal research.
	5.2.2 Pharma - Fusions & Acquisitions
Can Pfizer finally orchestrate a winning megamerger after so many disappointments? [FiercePharma] That of-course-they-did reaction to the Pfizer-Allergan merger agreement was followed by a series of analyst notes totting up the financial effects of the deal--the jobs Pfizer might cut, the costs it might save, the earnings that might accrete in the coming years, the buybacks it could fund with its overseas cash.
	5.2.3 Pharma - économie
Ex-GSK cancer chief Paoletti scores $29M war chest for multiple myeloma startup Kesios [FierceBiotech] That money will be put to use pursuing the nuclear factor kappa B (NF-kB) pathway, restoring apoptosis to eliminate certain white blood cells that play a big role in multiple myeloma, and then branching out to other tumor types.
Led By Biotech Stars, ORIC Nabs $53M To Fight Drug-Resistant Cancer [Xconomy] ORIC’s aim is to develop drugs for patients whose cancer has grown resistant to previous treatments. Its lead product, not yet in human testing, is aimed at prostate cancer that is no longer treatable with the drug enzalutamide.
	5.4 Traitements - Economie
A Look At Drug Pricing [In the Pipeline] Prices would rise in other countries if (say) Medicare were to be able to negotiate prices, a fact that many European governments are well aware of.
	5.7.1 SABCS-communiqués
Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients [Novartis] Novartis will present 55 abstracts showcasing key real-world data from Afinitor® (everolimus), Tykerb® (lapatinib) and several investigational compounds in advanced breast cancer.
	6. Lutte contre les cancers
Harvard cancer doctor out to transform medical research [STAT] Nadler directs the Harvard Catalyst program, which receives the NIH grants. He’s also dean of clinical and translational research at Harvard Medical School and a senior vice president at Dana-Farber, where he still sees patients once a week.
Researchers' New Best Friend [Wall Street Journal] “Compared to lab mice, with dogs they’re getting diseases within their natural life span, they’re exposed to the same pollutants in the environment” as humans."
	6.6 Publications
Cancer reproducibility project scales back ambitions [Nature News & Comment] Budget problems force replication project to drop one-quarter of its workload.
	6.7 DMP, Big Data & applis
In India, IBM's Watson Will Aid Cancer Care Where Doctors Are Scarce [Forbes] What takes a team of cancer doctors and oncology experts hours or even days today under normally busy conditions can instead be accomplished in a few minutes from a handheld device like an iPad, Merkel said. Physicians in India will be able to “apply this sea of knowledge” that exists for specific patients’ needs in a timely basis, Merkel added.